Syndax Q4 2022 Earnings Report
Key Takeaways
Syndax Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2022. The company had cash, cash equivalents, short-term and long-term investments of $481.3 million as of December 31, 2022. Two U.S. registrational filings are expected by the end of 2023.
Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023.
Topline data from the pivotal AGAVE-201 trial on track for mid-2023.
Two U.S. registrational filings expected by the end of 2023.
The fourth quarter was marked by significant progress on the clinical, regulatory and operational fronts.
Syndax
Syndax
Forward Guidance
For the first quarter of 2023, the Company expects research and development expenses to be $30 to $35 million and total operating expenses to be $40 to $45 million. For the full year of 2023, the Company expects research and development expenses to be $160 to $175 million and total operating expenses to be $225 to $240 million.